Rohan Lisa Cencia, Sassi Alexandra B
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
AAPS J. 2009 Mar;11(1):78-87. doi: 10.1208/s12248-009-9082-7. Epub 2009 Feb 5.
Microbicides have become a principal focus for HIV prevention strategies. The successful design of drug delivery systems for vaginal microbicide drug candidates brings with it a multitude of challenges. It is imperative that the chemical and physical characteristics of the drug candidate and its mechanism of action be clearly understood and considered to successfully deliver and target drug candidates efficiently. In addition, an understanding of the dynamic nature of the vaginal environment, the tissue and innate barriers present, as well as patient preferences are critical considerations in the design of effective microbicide products. Although the majority of drug candidates clinically evaluated to date have been delivered using conventional semisolid aqueous-based gel dosage forms, drug delivery system design has recently been extended to include advanced delivery systems such as vaginal rings, quick-dissolve films, and tablets. Ultimately, it may be necessary to develop multiple dosage platforms for a single active agent to provide users with options that can be used within the constraints of their social environment, personal choice, and environmental conditions.
杀微生物剂已成为艾滋病预防策略的主要焦点。为阴道杀微生物剂候选药物设计成功的给药系统带来了诸多挑战。必须清楚了解并考虑候选药物的化学和物理特性及其作用机制，以便成功有效地递送和靶向候选药物。此外，了解阴道环境的动态性质、存在的组织和固有屏障以及患者偏好是设计有效杀微生物剂产品的关键考虑因素。尽管迄今为止临床评估的大多数候选药物都是使用传统的半固体水基凝胶剂型给药的，但药物递送系统设计最近已扩展到包括阴道环、速溶薄膜和片剂等先进递送系统。最终，可能有必要为单一活性剂开发多种剂型平台，为用户提供可在其社会环境、个人选择和环境条件限制内使用的选择。
